Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Your search for Adex returned no results
Showing 1 to 15 of 16 results for alex

  1. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

    Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    8 August 2018

    Sections for TA536

  2. Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

    Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    24 January 2018
    View recommendations

    Sections for TA500

  3. Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (TA670)

    Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor.

    Technology appraisal guidance
    Published
    27 January 2021
    View recommendations

    Sections for TA670

  4. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  5. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  6. Technology appraisal committee C members

    Biographies and registered interests for members of the Technology Appraisal Committee C

  7. Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (TA1103)

    Evidence-based recommendations on lorlatinib (Lorviqua) for treating ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor in adults.

    Technology appraisal guidance
    Published
    21 October 2025

    Sections for TA1103

  8. PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites (HTG282)

    Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.

    HealthTech guidance
    Last updated
    19 July 2022
    View recommendations

    Sections for HTG282

  9. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  10. EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (HTG296)

    Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.

    HealthTech guidance
    Last updated
    8 October 2019
    View recommendations

    Sections for HTG296

  11. Mega Soft Patient Return Electrode for use during monopolar electrosurgery (HTG290)

    Evidence-based recommendations on Mega Soft Patient Return Electrode for use during monopolar electrosurgery.

    HealthTech guidance
    Published
    22 August 2012
    View recommendations

    Sections for HTG290

  12. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

    Highly specialised technologies guidance
    Discontinued

  13. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

    Technology appraisal guidance
    Discontinued

  14. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  15. Technology appraisal committee C members

    Biographies and registered interests for members of the Technology Appraisal Committee C